Gebhardt Brian J, Rajagopalan Malolan S, Gill Beant S, Heron Dwight E, Rakfal Susan M, Flickinger John C, Beriwal Sushil
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Pract Radiat Oncol. 2015 Nov-Dec;5(6):398-405. doi: 10.1016/j.prro.2015.06.013. Epub 2015 Jul 4.
Studies suggest equivalent pain relief from bone metastases after radiation therapy with >10-fraction regimens and shorter courses. Although American Society for Radiation Oncology evidence-based guidelines and the Choosing Wisely campaign endorse single-fraction treatments and caution against the use of extended courses, publications report single-fraction utilization rates below 5%. We evaluated the impact of our bone metastasis clinical pathway on the adoption of short-course palliative radiation in a large, integrated radiation oncology network.
We implemented a clinical pathway for the management of bone metastases in 2003 that required the entry of management decisions into an online tool that subjected off-pathway choices to peer review beginning in 2009. In 2014, the pathway was modified to encourage single-fraction treatments, and the use of >10 fractions was considered off pathway. Data were obtained from 16 integrated sites (4 academic, 12 community) from 2003 through 2014. Multivariate logistic regression was conducted to establish factors associated with treatment with a single fraction and with >10 fractions.
In this study, 12,678 unique courses were delivered. From 2003 to 2008, the single-fraction utilization rate was 7.6%. This increased to 10.9% from 2009 to 2013 and to 15.8% in 2014. The odds ratios for single-fraction use were 1.59 (95% confidence interval [CI], 1.39-1.81) and 2.58 (95% CI, 2.11-3.15) for 2009-2013 and 2014, respectively. Academic physicians were more likely to treat with a single fraction (odds ratio, 5.00; 95% CI, 4.38-5.71). Use of >10-fraction regimens significantly decreased from 18.6% in 2003-2008 to 15.2% in 2009-2013 and 9.7% in 2014.
Although our single-fraction utilization rate was initially in line with national rates (7.6%), the adoption rate increased to >15%. The use of >10-fraction regimens decreased significantly, predominantly among community practices. By 2014, >90% of courses were delivered with <10 fractions. This study demonstrates that provider-driven clinical pathways are able to standardize practice patterns and promote change consistent with evidence-based guidelines.
研究表明,采用超过10次分割方案和较短疗程的放射治疗对骨转移的疼痛缓解效果相当。尽管美国放射肿瘤学会循证指南和“明智选择”运动都支持单次分割治疗,并告诫不要使用延长疗程,但出版物报道单次分割的利用率低于5%。我们评估了我们的骨转移临床路径对在一个大型综合放射肿瘤学网络中采用短疗程姑息性放疗的影响。
我们在2003年实施了骨转移管理的临床路径,要求将管理决策录入一个在线工具,从2009年开始,对偏离路径的选择进行同行评审。2014年,该路径进行了修改,以鼓励单次分割治疗,使用超过10次分割被视为偏离路径。数据来自2003年至2014年的16个综合站点(4个学术站点,12个社区站点)。进行多变量逻辑回归以确定与单次分割治疗和超过10次分割治疗相关的因素。
在本研究中,共提供了12678个独特的疗程。2003年至2008年,单次分割利用率为7.6%。2009年至2013年增至10.9%,2014年增至15.8%。2009 - 2013年和2014年单次分割使用的优势比分别为1.59(95%置信区间[CI],1.39 - 1.81)和2.58(95%CI,2.11 - 3.15)。学术医生更倾向于采用单次分割治疗(优势比,5.00;95%CI,4.38 - 5.71)。超过10次分割方案的使用从2003 - 2008年的18.6%显著下降至2009 - 2013年的15.2%和2014年的9.7%。
尽管我们的单次分割利用率最初与全国水平一致(7.6%),但采用率增至超过15%。超过10次分割方案的使用显著下降,主要是在社区实践中。到2014年,超过90%的疗程采用少于10次分割。本研究表明,由提供者驱动的临床路径能够规范实践模式,并促进与循证指南一致的改变。